Bausch + Lomb Corp. Hits New 52-Week High at $18.91

Bausch + Lomb Corp. has reached a significant milestone by hitting a new 52-week high of USD 18.91 on February 25, 2026. This achievement underscores the company's notable performance within the Pharmaceuticals & Biotechnology sector, particularly as it has recorded a 23.92% increase over the past year, significantly outperforming the S&P 500, which saw a gain of 12.95% during the same period. With a market capitalization of USD 6,356 million, Bausch + Lomb operates as a small-cap entity in a competitive industry. The company's financial metrics reveal a debt-to-equity ratio of 0.73, indicating a manageable level of debt relative to its equity. However, it is important to note that the company is currently loss-making, as reflected by its negative return on equity of -3.88%. Additionally, the stock's price-to-book ratio stands at 0.99, suggesting that it is trading close to its book value. As Bausch + Lomb continues to navigate the dynamic landscape of the pharmaceuticals and biotechnology industry, this new high marks a noteworthy point in its ongoing journey.